Diligence memo · auto-generated · as of July 2, 2026
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
TAI Diagnostics, Inc. operates in Biotechnology, based in WAUWATOSA.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TAI Diagnostics, Inc. has raised $21M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2017-10-10.
Most recent recorded round closed around 2017-10-10.
Valuation (modeled)modeled
Provath models TAI Diagnostics, Inc. at approximately $464M (range $14M–$2.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.20× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 8.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 7.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.